Overview
Corporate Presentation
Email Alerts
Register to receive real time alerts
IR Contacts
Get in touch with our IR team
 |
We are developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio has a unique mechanism of action that targets cough centrally and peripherally and has the potential for a synergistic anti-tussive effect to treat chronic cough.
Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of chronic cough patients who currently have few treatment options.
Register to receive real time alerts